Sun Pharma Recalls Lisdexamfetamine Dimesylate 60mg Capsules Over Dissolution Failure
Sun Pharmaceutical Industries Inc. has initiated a Class II recall (D-0516-2025) for 5,448 bottles of Lisdexamfetamine Dimesylate 60mg capsules due to failed dissolution specifications. This voluntary, firm-initiated action, stemming from 9-month stability testing, impacts nationwide distribution. Procurement and supply chain leaders must assess immediate inventory risks and re-evaluate Sun Pharma's recurring quality control challenges, demanding robust corrective actions to mitigate future supply disruptions and regulatory exposure.
Recall Details: Summary of Quality Issues for Lisdexamfetamine Dimesylate
Sun Pharmaceutical Industries Inc. has initiated a Class II voluntary recall, identified as D-0516-2025, for a specific lot of Lisdexamfetamine Dimesylate Capsules, 60 mg. The affected product, packaged in 100-count bottles with NDC 57664-051-88, pertains to Lot # AD42648, which carries an expiration date of February 28, 2026. A total of 5,448 bottles are subject to this recall. The primary reason for this action is the product's failure to meet dissolution specifications, with out-of-specification (OOS) results identified during analysis at the 9-month long-term stability station, conducted under controlled conditions of 25°C and 60% relative humidity. For procurement directors, this event necessitates immediate action to identify and quarantine any stock from Lot # AD42648, incurring direct logistical costs for returns and potential revenue loss from unsaleable product. Regulatory affairs heads must ensure that all recall procedures are meticulously followed, including transparent communication with downstream partners and the FDA. The failure observed during stability testing suggests a potential degradation issue over time, directly impacting product efficacy and patient safety. This mandates a thorough investigation into the formulation, manufacturing processes by OHM Laboratories in New Brunswick, NJ, and packaging integrity by both the manufacturer and the distributor, Sun Pharmaceutical Industries Inc. of Cranbury, NJ.
Product and Market Impact: Lisdexamfetamine Dimesylate Supply Chain
Lisdexamfetamine Dimesylate is classified as a Schedule II controlled substance, a designation that underscores its critical therapeutic importance and the heightened regulatory scrutiny surrounding its production, distribution, and quality. The Class II recall status indicates that while the product's failure to meet dissolution specifications could lead to temporary or medically reversible adverse health consequences, the probability of serious adverse health consequences is considered remote. However, any compromise in drug release can directly impact patient outcomes, particularly for conditions like Attention-Deficit/Hyperactivity Disorder (ADHD) or Binge Eating Disorder (BED). This recall, initiated on June 16, 2025, with a center classification date of July 11, 2025, has a significant distribution footprint. The recalled units were initially distributed to 17 distributors, who then had the potential to further distribute the product nationwide across the United States. For supply chain VPs, this means assessing the immediate impact on stock availability for this specific lot and anticipating potential short-term supply gaps for Lisdexamfetamine Dimesylate. Maintaining a consistent supply of such a critical medication is paramount for market reputation and patient trust, making proactive inventory management and communication essential for all stakeholders in the supply chain.
Supply Chain Exposure: Downstream Implications for Distributors
The broad distribution pattern of the recalled Lisdexamfetamine Dimesylate, reaching 17 distributors with potential nationwide reach, creates significant operational challenges and exposure for downstream partners. These distributors are now directly responsible for identifying, isolating, and managing the return of the 5,448 affected bottles. This process is not merely a logistical exercise; it demands substantial resources for reverse logistics, meticulous inventory reconciliation, and comprehensive communication with pharmacies, healthcare providers, and ultimately, patients. For regulatory affairs heads at these distribution firms, ensuring strict adherence to FDA recall guidelines is critical to prevent secondary compliance issues. This includes accurate record-keeping of all recall activities, from initial notification to product disposition. Furthermore, such a recall can erode trust with end-users and prescribers, potentially impacting future sales and market share for both the distributor and Sun Pharmaceutical Industries Inc. Supply chain VPs must leverage this event to review and enhance their traceability systems, ensuring they can respond rapidly and efficiently to similar quality-related incidents in the future, thereby minimizing disruption and maintaining stakeholder confidence.
Alternative Sourcing Strategies: Mitigating Lisdexamfetamine Dimesylate Risk
The intelligence available does not identify specific alternative suppliers for Lisdexamfetamine Dimesylate. This absence of readily named alternatives significantly intensifies the supply risk associated with the current recall, placing a greater burden on procurement teams to secure continuity of supply for this critical Schedule II controlled substance. For procurement directors, this situation necessitates an immediate and proactive strategy to identify and qualify new potential suppliers. This involves extensive due diligence to locate other ANDA holders for Lisdexamfetamine Dimesylate, rigorously evaluating their manufacturing capabilities, quality management systems, and regulatory compliance history. The qualification process for a controlled substance can be protracted, potentially leading to extended periods of supply vulnerability if not addressed with urgency. Supply chain VPs should explore options for geographic diversification of their supplier base to build resilience against single-point-of-failure risks. Business development executives should monitor the competitive landscape for new market entrants or increased capacity from existing players to inform future sourcing decisions, ensuring long-term supply stability and mitigating reliance on a single, potentially compromised, source.
Sun Pharmaceutical Industries' Recurring Quality Challenges
This recall of Lisdexamfetamine Dimesylate is not an isolated incident for Sun Pharmaceutical Industries Inc., but rather another data point in a concerning pattern of recurring quality control vulnerabilities. The company has faced a consistent series of Class II recalls, signaling potential systemic issues within its quality management system and manufacturing processes, possibly across multiple facilities. Since January 2024, Sun Pharma has initiated at least eight other Class II recalls, demonstrating a persistent challenge in maintaining product quality and regulatory compliance. Notable prior incidents include: Mesalamine Tablets (microbial contamination, January 2024); Mesalamine Extended-Release Capsules (dissolution failure, March 2024); Febuxostat Tablets (microbial contamination, March 2024); Amphotericin B (assay failure, May 2024); XELPROS (Latanoprost) (particulate matter, May 2024); Nitrofurantoin (recurring dissolution failures, July 2024, though the recall was terminated, it highlighted persistent issues); Morphine Sulfate ER Tablets (dissolution specifications, March 2025); and Gabapentin (cross-contamination, April 2025). This pattern, particularly the repeated instances of dissolution failures, should prompt procurement directors to elevate their risk assessment for all products sourced from Sun Pharma. They must demand comprehensive audit reports and robust Corrective and Preventive Action (CAPA) plans. Regulatory affairs heads should anticipate heightened scrutiny from the FDA on Sun Pharma's operations, potentially leading to further regulatory actions like Warning Letters or Import Alerts, which could severely disrupt supply chains reliant on the company.
Remediation and Future Outlook: Navigating Regulatory Scrutiny
As an ongoing, firm-initiated Class II recall, Sun Pharmaceutical Industries Inc. is under strict obligation to conduct a comprehensive root cause investigation into the dissolution failure of Lisdexamfetamine Dimesylate. This investigation must precisely identify why out-of-specification results emerged at the 9-month stability station and lead to the implementation of effective Corrective and Preventive Actions (CAPA) to prevent recurrence. The FDA will closely monitor Sun Pharma's remediation efforts and the effectiveness of the recall. For procurement directors, demanding complete transparency and tangible evidence of robust CAPA implementation from Sun Pharma is paramount to ensure future product quality and supply reliability. Failure to adequately address these systemic quality issues could escalate regulatory consequences, potentially leading to more severe FDA actions such as Warning Letters, or even facility-specific Import Alerts, which would effectively halt product entry into the U.S. market. Supply chain VPs must develop robust contingency plans for potential long-term disruptions, considering the company's history of quality issues. Business development executives should closely monitor Sun Pharma's remediation progress, as sustained quality challenges can significantly impact market perception, competitive positioning, and the long-term viability of partnerships. This event underscores the critical need for continuous supplier performance monitoring and proactive risk management strategies across the industry.